American innovation
into China.
Chinese healthcare
into the world.
Healthcare, AI and global markets. Twenty years.
把美国的创新
带进中国,
把中国的医疗
带向世界。
医疗健康、AI 与全球市场。二十年。
I'm Chunyu Zhang — most people here call me Wendy. I've spent twenty years investing in healthcare: medical devices, pharmaceuticals, and more recently the AI systems changing how these companies get built. I work in both directions across the Pacific — helping U.S. healthcare companies find a real path into Asia, and helping Chinese healthcare and manufacturing companies reach markets they're usually told are closed to them. I put my own capital behind the ones I believe in.
What I work on
Market entry跨境商业化
Regulatory path, distribution partners, local manufacturing, the first ten customers. Not an introduction service — I stay in it until something ships.
Investing医疗投资
Medical devices, pharmaceuticals, healthcare services. I invest my own capital and work alongside founders, usually on the parts of the business that touch Asia.
AI in healthcareAI 与医疗
Where AI actually changes the work — research, diagnostics, how a company operates. I build software myself, which keeps me honest about how hard shipping is.
gobuddyai.comBackground
I started on the investing side of medical devices and pharmaceuticals, and moved toward AI as it became the thing actually changing how these companies get built. Healthcare has stayed the constant. I've sat on both sides of a cross-border deal often enough to know where they usually break — and the traffic runs both ways.
I'm an alumna of the Stanford Graduate School of Business. I work between Silicon Valley and Greater China.
-
Boya Bio-pharmaceutical博雅生物
Backed through its acquisition of Nanjing Xinbai Pharmaceutical. Exited.
-
Hanke Medical汉科医疗
Device CDMO and vascular intervention, running manufacturing in Ireland and Italy — a Chinese company operating European plants, the direction people assume doesn't happen.
-
MFII Healthcare Investment美创恒一医疗投资(香港)
A Hong Kong joint venture formed with an A-share listed medical company, set up to acquire and restructure healthcare assets. I serve as executive director.
-
SF Intra-City顺丰同城
Early investment in the on-demand logistics business. Exited.
我是张春雨(Wendy),跨境投资人。二十年来专注医疗健康领域投资——医疗器械、制药,以及正在改变这个行业的 AI。工作方向是双向的:帮美国医疗企业进入亚洲,也帮中国医疗与制造企业走向全球。我用自己的资金投我相信的公司。 斯坦福商学院(GSB)校友。
Writing
- 手术机器人监管进入第二阶段:FDA开始审查的,不只是机器,还有整支手术团队中文 · 2026-09-27
- Robotic Surgery Regulation Enters Its Second Phase: FDA Is Evaluating the Team, Not Just the MachineEN · 2026-09-27
- Make the Best Decision? Make the Decision Best.中文 · 2026-09-25
- Claude在DNA里发现“类CRISPR”新系统:AI做科研,走到了哪一步?中文 · 2026-09-25
- Claude Finds a “CRISPR-like” System in DNA: How Far Has AI Actually Come in Science?EN · 2026-09-25
- AI制药走到IPO门口:公开市场买的是平台,还是一支尚在一期的药?中文 · 2026-09-24
- AI Drug Discovery at the IPO Door: Is the Market Buying a Platform—or a Phase 1 Asset?EN · 2026-09-24
- FDA试验加速IND:新药融资更缺速度,还是更早知道哪里会失败?中文 · 2026-09-23
- Faster IND Development: Does Biotech Need More Speed—or Earlier Answers?EN · 2026-09-23
- SEC开放代币化股票五年试验:交易之外,股东权利如何落地?中文 · 2026-09-17
- The SEC’s Five-Year Tokenized Stock Experiment: How Will Shareholder Rights Work?EN · 2026-09-17
- Behind the $290M Round: What AI Drug Discovery Has to Cross Is More Than the ModelEN · 2026-09
- 2.9亿美元融资背后:AI制药真正要跨越的,不只是模型中文 · 2026-09
- AI真正的护城河,不在模型,而在工作流中文 + English Summary · 2026-09-15
Get in touch
I'm most useful to healthcare companies working out how to enter or expand across the Pacific, and to founders who want an investor who has done the operating side. If that's you, write to me directly.